Relevant Disclosure is attached.
Awaiting price reaction for this filing.
Fortis Healthcare reported consolidated revenue of INR 2,007 Cr in Q4 FY25, up 12.4% YoY, with operating EBITDA at INR 435 Cr (up 14.3%, margin 21.7%). For full year FY25, consolidated revenue grew 12.9% to INR 7,783 Cr, while operating EBITDA surged 25.3% to INR 1,588 Cr with margins expanding to 20.4% from 18.4% in FY24. Hospital business revenues rose 14.8% to INR 6,528 Cr with margins improving to 20.5% (vs 18.6%), supported by 9% ARPOB growth, occupancy rising to 69%, and a 72% jump in robotic surgeries. The Board recommended a dividend of INR 1 per share. Key strategic moves included acquiring the perpetual 'Fortis' brand rights for INR 200 Cr, consolidating the Agilus Diagnostics stake to 89.2%, signing definitive agreements to acquire Shrimann Hospital in Jalandhar, and divesting the Richmond Road Bengaluru facility. Net debt rose to INR 1,694 Cr (Net Debt/EBITDA at 0.93x vs 0.17x) primarily due to the Agilus acquisition.
Strong operational performance with healthy margin expansion and consistent revenue growth signals positive business momentum for shareholders. The higher debt from strategic acquisitions and brand buyout may temper near-term returns, but expanded capacity, focus specialty growth, and brand ownership reinforce long-term growth potential.